Range Cancer Therapeutics ETF (CNCR)
10.66
-0.08
(-0.74%)
USD |
NASDAQ |
Mar 21, 16:00
10.68
+0.02
(+0.19%)
After-Hours: 20:00
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| -- | -- | -- | -- |
| Weighted Average Dividend Yield | Turnover Ratio (Generic) | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| -- | -- | -- | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks to track the total return performance of the Range Cancer Therapeutics Index. The Index tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts ("ADRs") with a market capitalization of more than $250 million. |
| General | |
| Security Type | Exchange-Traded Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Loncar |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of March 22, 2025.
Asset Allocation
As of February 28, 2025.
| Type | % Net |
|---|---|
| Cash | 0.32% |
| Stock | 99.28% |
| Bond | 0.40% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 0.00% |
Basic Info
| Investment Strategy | |
| The Fund seeks to track the total return performance of the Range Cancer Therapeutics Index. The Index tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts ("ADRs") with a market capitalization of more than $250 million. |
| General | |
| Security Type | Exchange-Traded Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Loncar |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |